Clinical Trial Update: Predictive Value of Innovative Prognostic Markers (Gut Microbiota, Sarcopenia, Metabolic Syndrome and Obesity) on Surgical and Oncologic Results in the Management of Sporadic Colorectal Adenocarcinoma.

View source ↗

Summary

This clinical trial evaluates whether innovative prognostic markers such as gut microbiota, sarcopenia, metabolic syndrome, and obesity can predict surgical and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Snippet

Sponsor: University Hospital, Clermont-Ferrand | Conditions: Colorectal Neoplasms, Microbiota | Status: UNKNOWN